10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lifted its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 140.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 151,693 shares of the company’s stock after purchasing an additional 88,583 shares during the period. Schonfeld Strategic Advisors LLC’s holdings in 10x Genomics were worth $2,178,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Signaturefd LLC grew its holdings in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after purchasing an additional 1,452 shares during the period. Blue Trust Inc. boosted its holdings in 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after purchasing an additional 1,299 shares during the last quarter. Sound Income Strategies LLC grew its stake in shares of 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after buying an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of 10x Genomics during the 4th quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. lifted its holdings in 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock valued at $70,000 after acquiring an additional 4,324 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares of the company’s stock, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.03% of the company’s stock.

10x Genomics Stock Performance

Shares of TXG opened at $8.61 on Tuesday. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $28.25. The stock has a market capitalization of $1.05 billion, a PE ratio of -5.66 and a beta of 1.94. The stock has a 50-day simple moving average of $9.10 and a 200-day simple moving average of $12.73.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

TXG has been the subject of several recent analyst reports. Canaccord Genuity Group cut their target price on 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. UBS Group reduced their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Morgan Stanley dropped their price target on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $18.85.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.